REQUEST A DEMO
Total
USD $0.00
Search more companies

Grindeks AS (Latvia)

Main Activities: Pharmaceutical and Medicine Manufacturing | Pharmaceutical Preparation Manufacturing | Drugs and Druggists' Sundries Merchant Wholesalers
Full name: Grindeks AS Profile Updated: February 25, 2026
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English & Russian Download a sample report

grindeks's generics and active pharmaceutical products include pharmaceutical related to cardiovascular, psychotropic, analgesic, cough, flu and anti-cancer medications. It also makes over-the-counter products and active Pharmaceutical ingredients. The company's products enable the patients to get access to high-quality, safe and modern medicines.

Headquarters
Krustpils iela 53
Riga; Riga; Postal Code: 1057

Contact Details: Purchase the Grindeks AS report to view the information.

Website: http://www.grindeks.lv

Basic Information
Total Employees:
Purchase the Grindeks AS report to view the information.
Outstanding Shares:
Purchase the Grindeks AS report to view the information.
Registered Capital:
Purchase the Grindeks AS report to view the information.
Financial Auditors:
Purchase the Grindeks AS report to view the information.
Incorporation Date:
October 11, 1991
Key Executives
Purchase this report to view the information.
Chairman of the Supervisory Board
Ownership Details
Purchase this report to view the information.
96.88%
Purchase this report to view the information.
0.1%
Purchase this report to view the information.
0.08%
Purchase this report to view the information.
0.07%
Purchase this report to view the information.
0.05%
Subsidiaries
Grindeks Rus Ltd.
100%
HBM Pharma Ltd. (Slovakia)
100%
Namu apsaimniekosanas projekti Ltd.
100%
Company Performance
Financial values in the chart are available after Grindeks AS report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency EUR. Absolute financial data is included in the purchased report.
Net sales revenue
-12.36%
Total operating revenue
-11.08%
Operating Profit/Loss (EBIT)
-80.03%
EBITDA
-80.03%
Net Profit/Loss for the Period
N/A
Total Assets
-14.64%
Total Equity
-23.15%
Operating Profit Margin (ROS)
-3.37%
Net Profit Margin
N/A
Return on Equity (ROE)
N/A
Quick Ratio
-0.36%
Cash Ratio
0.01%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?